{"filings":[{"id":2088329,"accession_number":"0001171843-26-005292","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-08-06T11:30:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q2 net loss $25.2M; tovecimig ORR improves to 18.0% with p=0.0228","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.2M ($0.13/sh) vs $19.9M ($0.14/sh) in Q2 2025; R&D spend rose 19% to $19.6M.","Cash and marketable securities $180M as of June 30, 2026; runway into 2028.","Tovecimig Phase 2/3 ORR improved to 18.0% (20/111) with p=0.0228 vs paclitaxel 5.3%.","FDA feedback on tovecimig data expected Q3 2026; BLA submission planned later this year.","CTX-8371 cohort expansions enrolling; CTX-10726 Phase 1 dosed; CTX-471 Phase 2 starts Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1389878,"accession_number":"0001171843-26-004428","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-07-01T21:00:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"Compass Therapeutics reports tovecimig Phase 2/3 COMPANION-002 met primary endpoint; BLA filing planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel achieved ORR 18.0% vs 5.3% paclitaxel alone (p=0.0228); median PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001).","OS analysis confounded by 54% crossover; post-hoc subset shows median OS 12.8 mo for crossover patients vs 6.1 mo for no-crossover (HR=0.54, p=0.04).","Cash and marketable securities $195M as of Q1 2026; runway into 2028. FDA meeting expected Q3 2026, BLA filing late 2026, potential approval 2H 2027.","Pipeline includes CTX-8371 (PD-1xPD-L1) with deep responses in TNBC, HL, NSCLC; CTX-471 (CD137) Phase 2 in NCAM+ tumors mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1203617,"accession_number":"0001171843-26-004224","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-06-22T21:45:16+00:00","items":["5.03","9.01"],"status":"ready","headline":"Compass Therapeutics adopts new bylaws establishing exclusive federal forum for Securities Act claims","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Second Amended and Restated Bylaws effective June 22, 2026.","New bylaws require Securities Act of 1933 claims to be brought in U.S. District Courts for Delaware or Massachusetts.","Previous bylaws from July 17, 2020 restated in entirety.","Change is procedural; no impact on operations or financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":999757,"accession_number":"0001171843-26-004068","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-06-11T20:00:49+00:00","items":["5.07"],"status":"ready","headline":"Stockholders re-elect Schuetz & Lindahl, ratify CohnReznick, approve exec compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Thomas J. Schuetz elected with 102,984,184 for, 18,837,499 withheld; Richard S. Lindahl with 103,453,540 for, 18,368,143 withheld.","CohnReznick LLP ratified as independent auditor for FY 2026 (137,896,097 for, 181,037 against).","Non-binding advisory vote on executive compensation approved (117,963,684 for, 1,796,022 against).","Shareholders voted for annual say-on-pay frequency (118,289,260 for every year); board adopted annual frequency.","All proposals passed with no surprises; broker non-votes reported for director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95094,"accession_number":"0001171843-26-003005","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.","Company plans FDA meeting then BLA submission for tovecimig in second-line BTC by end of 2026.","CTX-8371 cohort expansions in TNBC, NSCLC, HL initiated; dose-escalation data at ASCO 2026 poster.","CTX-10726 Phase 1 study initiated; initial clinical data expected in Q4 2026.","Cash and marketable securities $195M at Q1 2026; net loss $18.3M ($0.10/share); cash runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95093,"accession_number":"0001171843-26-002720","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).","Primary ORR (previously announced) was 17.1% vs 5.3% (p=0.031); one complete response in tovecimig arm.","OS endpoint not met due to 54% crossover; ITT OS 8.9 vs 9.4 months (HR=1.05, p=0.78).","Crossover patients had median OS 12.8 months vs 6.1 months for non-crossover (HR=0.54, p=0.04).","Company intends to meet with FDA to discuss data in advance of a planned BLA submission for second-line BTC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107921,"accession_number":"0001171843-26-001336","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.","Cash and marketable securities $209M as of Dec 31, 2025; expected runway into 2028.","Tovecimig COMPANION-002 PFS/OS analyses expected in April 2026 after reaching 80% OS events.","CTX-8371 expansion cohorts enrolling in TNBC and NSCLC; initial data expected Q2 2026.","CTX-10726 IND cleared; Phase 1 enrolling in Q1 2026; Bing Gong promoted to CSO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107920,"accession_number":"0001171843-26-000083","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.","Analyses of PFS and OS in tovecimig Phase 2/3 BTC trial expected late Q1 2026; BLA preparation underway.","CTX-8371: third confirmed response in Hodgkin Lymphoma; expansions open in TNBC and NSCLC.","Appointed Arjun Prasad as CCO and Cynthia Sirard as CMO effective January 2026.","CTX-10726 Phase 1 initiation expected Q1 2026 with initial data in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124335,"accession_number":"0001171843-25-007004","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).","Cash and marketable securities $220M as of Sep 30, 2025, up from $127M Dec 2024; cash runway through 2028.","Tovecimig: OS and PFS data from Phase 2/3 COMPANION-002 in BTC expected late Q1 2026.","CTX-8371 Phase 1 fully enrolled, no DLTs; cohort expansions in NSCLC and TNBC start Q4 2025; data H1 2026.","CTX-10726 IND filing on track for Q4 2025; initial Phase 1 data expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141013,"accession_number":"0001193125-25-179958","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.","Net proceeds estimated at $112.5M (base), up to $129.5M if underwriters' 30-day option for 6M additional shares is exercised.","Proceeds to fund commercial readiness, R&D of product candidates, and general corporate purposes.","Cash and equivalents expected to fund operations into 2028.","Jefferies, Piper Sandler, and Guggenheim Securities are joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141012,"accession_number":"0001171843-25-005260","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.","Tovecimig Ph2/3 BTC trial met primary endpoint (ORR 17.1% vs 5.3%, p=0.031); OS analysis delayed to Q1 2026 due to fewer deaths.","CTX-8371 Ph1: confirmed PR in NSCLC with 100% target lesion reduction and TNBC with >90% reduction; expansion cohorts planned Q4 2025.","CTX-10726 (PD-1 x VEGF-A) showed superior PD-1 inhibition and tumor control vs ivonescimab preclinically; IND filing on track for Q4 2025.","Cash and marketable securities $101M as of June 30, 2025; expected cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158787,"accession_number":"0001171843-25-003868","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Therapeutics annual meeting elects three directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl L. Gordon, Philip J. Ferneau, and James P. Boylan elected as Class II directors with 80.7M, 58.3M, and 83.6M votes for, respectively.","Ratification of CohnReznick LLP as auditor for FY2025 approved with 114.3M for, 28,647 against, 22,788 abstain.","Broker non-votes of 29,432,541 on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158786,"accession_number":"0001171843-25-002952","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics: Tovecimig meets primary endpoint in BTC trial; Q1 net loss $16.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel achieved 17.1% ORR (incl. 1 complete response) vs 5.3% for paclitaxel alone (p=0.031) in Phase 2/3 BTC study.","Secondary endpoints PFS, OS, DoR analyses expected Q4 2025; pre-specified event count not yet met.","Q1 2025 net loss $16.6M ($0.12/sh), R&D $13.1M (+37% YoY), cash $113M providing runway into 2027.","CTX-10726 (PD-1 x VEGF-A) pre-IND meeting completed; IND filing expected Q4 2025.","CTX-8371 Phase 1 dose-escalation advanced to 4th cohort with no DLTs; preliminary data H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158785,"accession_number":"0001171843-25-001900","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.","One complete response in combo arm; progressive disease rate 16.2% vs 42.1%.","Secondary endpoints (PFS, OS, DoR) not yet mature; expected Q4 2025 after 80% event threshold.","Safety consistent with prior studies; DMC recommended continuation after four reviews.","BTC affects ~23,000 US patients annually; ~85% lack approved second-line targeted therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177190,"accession_number":"0001171843-25-001105","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).","Cash and marketable securities $127M, down from $152M; cash runway into 2027.","Top-line data from COMPANION-002 (tovecimig in BTC) on track for end of Q1 2025.","Phase 2 trials for tovecimig in DLL4+ CRC and CTX-471 in NCAM+ tumors expected mid-2025.","CTX-10726 IND filing expected year-end 2025; CTX-8371 Phase 1 third cohort enrolled, no DLTs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":850000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177189,"accession_number":"0001171843-25-000116","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.","Top-line Phase 2/3 data for tovecimig (CTX-009) in BTC expected end of Q1 2025.","New drug candidate CTX-10726 (PD-1 x VEGF-A bispecific) advancing; IND submission targeted by YE 2025.","Third dosing cohort fully enrolled for CTX-8371 Phase 1; preliminary data H2 2025.","Two Phase 2 biomarker trials planned for mid-2025: tovecimig in DLL4+ CRC and CTX-471 in NCAM/CD56+ tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193967,"accession_number":"0001171843-24-006847","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Compass Therapeutics appoints Barry Shin as CFO; Neil Lerner as PAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barry Shin named CFO effective Dec 9, 2024; base salary $475K, target bonus 45%, sign-on $50K, and equity grants of 800K shares total.","Neil Lerner appointed principal accounting officer; he was VP of Finance since November 2020.","Shin replaces Thomas Schuetz as principal financial officer; Schuetz remains CEO.","Press release highlights 2025 catalysts: topline data for CTX-009 expected in Q1 2025.","Shin previously served as CFO/COO at Trevena and held investment banking roles at Mizuho, Guggenheim, and Piper Sandler."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193966,"accession_number":"0001171843-24-006247","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.","Cash and marketable securities $135M as of Sep 30, 2024; runway into Q1 2027.","Phase 2/3 CTX-009 BTC trial fully enrolled; top-line data expected end of Q1 2025.","CTX-009 Phase 2 in DLL4-positive CRC second-line planned for mid-2025.","CTX-471 Phase 2 trial in NCAM-expressing tumors planned for mid-2025 based on biomarker data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":850000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210290,"accession_number":"0001171843-24-004669","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.","Cash and marketable securities $146M as of June 30, 2024; cash runway into Q1 2027.","Completed enrollment (n=150) in COMPANION-002 Phase 2/3 trial of CTX-009 in BTC; top-line data expected Q1 2025.","Stage 1 of COMPANION-003 in CRC showed ORR 5%, median PFS 3.9 months, median OS 10.2 months; designing second-line DLL4+ study.","Discontinuing CTX-471 + KEYTRUDA combo due to cytokine suppression; planning Phase 2 monotherapy with new biomarker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":850000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228599,"accession_number":"0001171843-24-003463","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Therapeutics shareholders elect Chiniara and Gray, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ellen V. Chiniara received 76,766,213 for and 23,754,485 withheld as director.","Mary Ann Gray received 100,051,792 for and 468,906 withheld as director.","Broker non-votes for director proposals were 17,705,143.","Ratification of CohnReznick as auditor passed 118,180,952 for, 13,785 against, 31,104 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228598,"accession_number":"0001171843-24-003129","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Compass Therapeutics CEO Vered Bisker-Leib resigns; Thomas Schuetz appointed CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vered Bisker-Leib, PhD, MBA resigned as CEO and board member effective May 28, 2024, not due to any disagreement.","Thomas Schuetz, MD, PhD (President of R&D, Vice Chair) appointed President and CEO, and Principal Executive/Financial/Accounting Officer.","Separation agreement: 18 months base salary, up to 18 months COBRA reimbursement, release of claims.","Consulting agreement: 15 months at $45,000 annual fee; outstanding equity continues vesting during consultancy.","Schuetz previously served as CEO; returns to role; Board of Directors reduced to seven members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228597,"accession_number":"0001171843-24-002784","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.","Cash and marketable securities $156.3M at March 31, 2024; cash runway into late 2026.","FDA Fast Track for CTX-009 in BTC; COMPANION-002 enrollment to complete mid-2024, data Q1 2025.","Stage 1 of COMPANION-003 (CRC) enrollment complete; top-line data expected by mid-2024.","CTX-8371 first patient dosed in April 2024; Phase 2 planned for CTX-471 in melanoma with biomarker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228596,"accession_number":"0001171843-24-002220","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants Fast Track Designation for Compass's CTX-009 in biliary tract cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation for CTX-009 (bispecific DLL4/VEGF-A antibody) + paclitaxel in previously treated metastatic/locally advanced biliary tract cancer.","Phase 2 data showed ORR 37.5% (9/24), median PFS 9.4 months, median OS 12.5 months.","Enrollment in Phase 2/3 COMPANION-002 study expected to complete mid-2024; top-line data by year-end 2024.","Co-founder Thomas Schuetz highlighted large unmet need with current single-digit response rates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247247,"accession_number":"0001171843-24-001515","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.","Cash and marketable securities $152.5M at Dec 31, 2023; runway into mid-2026.","CTX-009 Phase 2/3 BTC study (COMPANION-002) enrollment ongoing; top-line data expected year-end 2024.","CTX-009 Phase 2 CRC study (COMPANION-003) Stage 1 enrollment complete; top-line data mid-2024.","CTX-471 Phase 2 monotherapy planning underway for melanoma with novel biomarker; combination arm with KEYTRUDA enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247246,"accession_number":"0001171843-24-000164","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Compass Therapeutics appoints Bisker-Leib as CEO, Schuetz to President of R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vered Bisker-Leib appointed CEO effective Jan 9, 2024; salary increased to $600k, target bonus 55%.","Thomas Schuetz transitions from CEO to President of R&D and Vice Chair of Board.","Bisker-Leib receives options for 1,753,125 shares and RSUs for 1,753,125 shares at $1.93 exercise price.","Schuetz receives options for 637,500 shares and RSUs for 637,500 shares at $1.93.","Preliminary unaudited cash, equivalents and marketable securities approx $152M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247245,"accession_number":"0001171843-24-000082","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Compass Therapeutics: CEO change to Bisker-Leib, CTX-471 CR in SCLC, $152M cash","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO succession: Vered Bisker-Leib appointed CEO effective Jan 9, 2024; Thomas Schuetz becomes President of R&D and Vice Chair.","Year-end 2023 cash & securities ~$152M, providing runway into mid-2026.","CTX-471: SCLC patient partial response converted to complete response; new PR in melanoma yields 27% ORR (3/11).","CTX-009: COMPANION-003 top-line data expected mid-2024; COMPANION-002 top-line data in H2 2024.","CTX-8371 IND accepted; first patient dosing expected in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264678,"accession_number":"0001171843-23-006911","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Q3 net loss $10.0M ($0.08/shr); cash $164M; CEO succession to Bisker-Leib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2023 was $10.0M ($0.08/shr) vs $12.0M ($0.12/shr) in Q3 2022; 9-month net loss $29.1M.","Cash and marketable securities $164M as of Sep 30, 2023, providing cash runway into 2026.","CEO succession: President/COO Vered Bisker-Leib to become CEO; current CEO Thomas Schuetz to President of R&D and Vice Chair, effective Jan 9, 2024.","CTX-009 Ph2/3 COMPANION-002 (BTC) top line data expected H2 2024; initial data from COMPANION-003 (CRC) expected by year-end 2023.","CTX-8371 IND cleared; Phase 1 trial to start Q4 2023. CTX-471 dose-escalation completed; expansion expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281915,"accession_number":"0001171843-23-004946","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q2 net loss $11.3M; BTC top-line data pushed to H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M ($0.09/share) in Q2 2023 vs $8.5M loss ($0.08/share) in Q2 2022.","Cash and marketable securities $169M as of June 30, 2023; cash runway into 2026.","R&D expense $10.2M in Q2 2023, up 74% YoY driven by CTX-009 clinical and manufacturing costs.","CTX-009 Phase 2 CRC initial data still expected H2 2023; BTC top-line data delayed to H2 2024 due to slower enrollment.","CTX-8371 (PD-1 x PD-L1) IND submission targeted Q3 2023 with Phase 1 start in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300913,"accession_number":"0001171843-23-003943","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Therapeutics announces results of 2023 annual meeting of stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Thomas J Schuetz and Richard S Lindahl as Class III directors for three-year terms.","Schuetz: 67,240,784 for, 17,368,756 withheld; Lindahl: 84,596,658 for, 12,882 withheld.","Ratified CohnReznick LLP as independent auditor for 2023: 96,574,239 for, 130,740 against, 24,542 abstained.","Broker non-votes: 12,119,981 on director election; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300912,"accession_number":"0001171843-23-002866","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q1 net loss $7.8M; cash $175M funds operations into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.8M ($0.06 per share) vs $7.2M in Q1 2022; R&D spend up 50% to $6.6M on CTX-009.","Cash and marketable securities $175M at March 31, 2023, providing runway into 2026.","Phase 2/3 of CTX-009 in biliary tract cancers enrolling; top-line data expected H1 2024.","Phase 2 CTX-009 in colorectal cancer initial data expected Q3 2023; ASCO GI data showed 37.5% ORR.","Appointed Minori Rosales as SVP Head of Clinical Development and Richard Lindahl to board as Audit Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300911,"accession_number":"0001171843-23-002480","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Compass Therapeutics appoints Richard S. Lindahl to Board and Audit Committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard S. Lindahl appointed as Class III director effective April 21, 2023; term expires at 2023 annual meeting.","Also appointed chairman of Audit Committee; qualifies as independent director and audit committee financial expert.","Compensation: $45,000 cash retainer, $10,000 additional for Audit Committee chair; 50,000 share option award vesting monthly over four years.","No family relationships or reportable transactions with the Company or its officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320801,"accession_number":"0001171843-23-001585","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Compass Therapeutics confirms no cash deposits or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company explicitly states it holds no cash deposits at Silicon Valley Bank.","Also holds no securities at Silicon Valley Bank.","Disclosure made under Regulation FD on March 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320800,"accession_number":"0001171843-23-001157","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Compass Therapeutics board member David Wurzer resigns for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Wurzer resigned from the Board and all committees effective February 20, 2023.","Resignation was for personal family reasons, not due to any disagreement with the Company.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320799,"accession_number":"0001171843-23-000899","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Compass Therapeutics appoints David Wurzer to Board and as Audit Committee Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Wurzer appointed as Class III director effective Feb 8, 2023.","Wurzer named Chairman of Audit Committee; independent and audit committee financial expert.","Compensation: $45,000 cash retainer plus $10,000 for Audit Chair; 50,000-share option award vesting over 4 years.","Wurzer is CFO of Enko Chem, Inc.; no family relationships or reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320798,"accession_number":"0001171843-23-000338","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Compass Therapeutics reports positive Phase 2 data for CTX-009 in biliary tract cancers; ORR 37.5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX-009 + paclitaxel achieved 37.5% ORR in 24 patients; second-line sub-group ORR 63.6% (7/11 PRs).","Median PFS 9.4 months, median OS 12.5 months; data to be presented at ASCO GI on Jan 20, 2023.","Randomized Phase 2/3 trial (up to 150 patients) initiated in US; may enable BLA submission in H2 2024.","Safety consistent with prior studies; Grade 3+ TEAEs included decreased neutrophils (83.3%), hypertension (16.7%).","Investor webcast scheduled for Jan 23 at 8:30am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338942,"accession_number":"0001171843-22-007714","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Compass Therapeutics CSO Susan Kalled departs effective Nov 29, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Kalled, PhD, resigned as Chief Scientific Officer on November 29, 2022.","Entitled to 12 months base salary severance paid in installments over 12 months.","Eligible for up to 12 months COBRA premium reimbursement, contingent on separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338941,"accession_number":"0001171843-22-007012","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["1.01","5.02","3.02","9.01"],"status":"ready","headline":"Compass Therapeutics raises $80M in PIPE led by Enavate; extends cash runway to 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 25M shares at $3.21 each for gross proceeds of ~$80M; closing expected by Nov 8, 2022.","PIPE led by Enavate Sciences with participation from Janus Henderson, Vivo Capital, OrbiMed, and others.","New director James P. Boylan (CEO of Enavate) appointed to board, effective upon closing.","Proceeds to fund CTX-009, CTX-471, CTX-8371 clinical programs and preclinical work; cash runway extended into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356313,"accession_number":"0001171843-22-005763","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Compass Therapeutics director Stephen Squinto resigns from board effective Aug 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Squinto, Ph.D., notified Compass of his resignation from the Board and all committees, effective August 31, 2022.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","Dr. Squinto had been a Board member since 2015, representing an early investor; he is leaving to pursue other professional endeavors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356312,"accession_number":"0001193125-22-207806","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Compass Therapeutics enters ATM with Jefferies for up to $75M; terminates B. Riley facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Open Market Sale Agreement with Jefferies to sell up to $75M of common stock via ATM offering.","Prior ATM agreement with B. Riley Securities terminated effective July 29, 2022.","Jefferies receives up to 3% commission and up to $75K expense reimbursement; Compass not obligated to sell.","Sales will be made under effective S-3 registration statement (333-257821) and prospectus supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374695,"accession_number":"0001171843-22-004019","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Therapeutics stockholders elect directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Philip J. Ferneau re-elected with 57.0M votes for, 8.5M withheld; Carl L. Gordon with 55.5M for, 10.0M withheld.","Ratification of CohnReznick LLP as auditor for FY 2022 passed with 82.3M for, 65,654 against, 5,702 abstain.","No other proposals or material changes disclosed at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374694,"accession_number":"0001171843-22-003159","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Compass reports CTX-009 42% ORR in biliary tract cancers; to start U.S. Phase 2 in Q3 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX-009 + paclitaxel achieved 42% ORR (10 PRs) out of 24 patients with advanced biliary tract cancers.","Clinical benefit rate 92% (22/24 patients had PR or stable disease); responses across all four BTC subtypes.","Safety consistent with Phase 1: common AEs included hypertension (50%) and neutropenia (54.2%); manageable.","Plans to initiate Stage 2 of Phase 2 study in the U.S. in Q3 2022, following Simon Two-Stage design criteria met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374693,"accession_number":"0001171843-22-002790","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Compass Therapeutics appoints Chiniara and Gray to board; Toledano departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ellen Chiniara (former Alexion Chief Legal Officer) and Mary Ann Gray (Gray Strategic Advisors) join as Class I directors.","Both deemed independent; Chiniara also appointed to Nominating/Governance and Compensation committees.","Each non-employee director receives $45K cash retainer and initial option on 45,000 shares vesting over four years.","Miranda Toledano will not stand for reelection at May 24, 2022 annual meeting; no disagreement cited.","Appointments aim to support pipeline advancement and shareholder value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393164,"accession_number":"0001193125-22-054600","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Compass Therapeutics director Brett Kaplan resigns from Board effective Feb 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Kaplan, M.D. resigned from the Board and all committees, effective February 25, 2022.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","No replacement announced; Board composition changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393163,"accession_number":"0001171843-22-000369","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Compass Therapeutics' CTX-009 Phase 2 study in biliary tract cancers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CTX-009 bispecific antibody targeting DLL4 and VEGF-A.","Enables global Phase 2 trial in advanced biliary tract cancers including cholangiocarcinoma.","Will expand ongoing South Korean Phase 2; US clinical sites expected to open in Q2 2022.","CEO Thomas Schuetz noted CTX-009 has potential as important new therapy for BTC patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411640,"accession_number":"0000950170-21-005307","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Julie Sunderland resigns from Compass Therapeutics Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julie Sunderland notified the Board of her resignation effective December 31, 2021.","Resignation from the Board and all committees; not due to any disagreement with the company.","She was an early venture investor and is departing for other professional endeavors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411639,"accession_number":"0000950170-21-002863","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics prices $125M public offering of 35.7M shares at $3.50; uplists to Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 35,715,000 shares at $3.50/share; underwriters have 30-day option for additional 5,357,250 shares.","Gross proceeds ~$125M; net proceeds after discounts and expenses ~$117.3M.","Common stock to trade on Nasdaq Capital Market under ticker CMPX starting November 2, 2021.","SVB Leerink is book-running manager; Raymond James, Wedbush, H.C. Wainwright as passive book-runners.","Net proceeds to fund ongoing operations including clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411638,"accession_number":"0000950170-21-002562","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Compass reports CTX-009 Phase 2a ORR 29% in BTC; proposes public offering and Nasdaq uplist","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX-009 Phase 2a in biliary tract cancer met criteria to advance; 5 partial responses in 17 patients (ORR 29%), 100% clinical benefit rate.","Compass plans to submit US IND this quarter, initiate Phase 2 study in Q2 2022.","Preliminary cash $25.5M as of Sep 30, 2021; proposes underwritten public offering of common stock plus 15% option for underwriters.","Common stock approved for Nasdaq Capital Market listing under symbol CMPX, subject to offering pricing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411637,"accession_number":"0000950170-21-002075","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2021-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Compass Therapeutics reports CTX-009 Phase 1 data: 19% ORR at RP2D in heavily pre-treated tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX-009 monotherapy achieved 19% ORR (3/16) at RP2D (10.0-12.5 mg/kg) and 69% DCR.","Across all doses, ORR was 8% (4 partial responses) and DCR was 62% in heavily pre-treated patients (median 3 prior lines).","Treatment well tolerated; no dose-limiting toxicities; hypertension in 38% (17/45), 7 Grade 3.","94% of colorectal and 58% of gastric patients had prior anti-VEGF therapy (bevacizumab/ramucirumab).","Phase 1b combo and Phase 2 studies underway; Compass holds global rights except S. Korea and China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430396,"accession_number":"0000950170-21-000831","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K/A","filed_at":"2021-08-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Compass Therapeutics merger with Trigr completed; Trigr had $99k cash, $15.8M deficit","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Trigr audited 2020: cash $99k, total liabilities $2.57M, net loss $2.11M, accumulated deficit $15.8M; going concern doubt.","Trigr unaudited Q1 2021: cash $4.3M, net income $5.6M from $7M licensing revenue to Elpiscience.","Merger consideration: 10.27M Compass shares at $4.90/share (~$50.3M) plus up to $9M earnout.","Trigr lead asset CTX-009 licensed to Elpiscience for Greater China; $7M upfront, up to $110M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}